Real-world first-line atezolizumab for stage IV NSCLC with PD-L1 ≥50% in Türkiye

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, multicenter observational study will collect routine clinical data from about 150 patients treated with first-line atezolizumab across several Turkish hospitals. No protocol-mandated interventions are required; treatments, imaging, labs, and follow-up occur per each center's standard practice. Investigators will analyze survival, response, safety, and real-world treatment patterns using information abstracted from medical records. The goal is to describe how atezolizumab performs outside of controlled trials in a national cohort.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Signed informed consent form.
* Diagnosis of stage IV non-small cell lung cancer.
* Male or female patients aged 18 years or older.
* Patients who have been prescribed atezolizumab in accordance with routine clinical practice and the locally approved indication in Türkiye.
* Patients who have received up to 3 cycles of atezolizumab at the screening visit.

Exclusion Criteria:

* Patients who are not receiving atezolizumab for the treatment of lung cancer according to standard of care and the approved indication.
* Known or suspected hypersensitivity to atezolizumab.
* Pregnant or breastfeeding women.

Where it's running

• Adana City Hospital
  Adana, Turkey (Türkiye) Recruiting
• Afyonkarahisar Health Sciences University Hospital
  Afyonkarahisar, Turkey (Türkiye) Recruiting
• Ankara Atatürk Sanatoryum Training and Research Hospital
  Ankara, Turkey (Türkiye) Recruiting
• Antalya Training and Research Hospital
  Antalya, Turkey (Türkiye) Recruiting
• Antalya City Hospital
  Antalya, Turkey (Türkiye) Recruiting
• Adnan Menderes University Faculty of Medicine Hospital
  Aydin, Turkey (Türkiye) Recruiting

Study contacts

• Study coordinator: Derya Kıvrak Salim
• Email: derya.kivraksalim@sbu.edu.tr
• Phone: +90 533 648 82 17

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining dTACE-HAIC with Bevacizumab and Atezolizumab for treating large liver cancer

  This study is testing a new combination treatment for people with large liver cancer to see if it works better than current options for those who can't have surgery.

  Recruiting Sun Yat-sen University · Beijing, None Selected · NCT06609863

• Combining Atezolizumab and Pirfenidone for Advanced Lung Cancer

  This study is testing if adding pirfenidone to atezolizumab can help people with advanced lung cancer who have already been treated feel better and fight their cancer more effectively.

  Recruiting Phase 1/2 University of Kansas Medical Center · Fairway, Kansas and 1 other locations · NCT04467723

• Blood biomarkers to predict response to atezolizumab plus bevacizumab in hepatocellular carcinoma

  This study tests whether blood-based biomarkers can predict which patients with advanced liver cancer will respond to first-line atezolizumab plus bevacizumab.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07734857

• BL-M14D1 with Atezolizumab for extensive-stage small cell lung cancer

  This phase 2 trial tests whether adding BL-M14D1 to atezolizumab helps people with extensive-stage small cell lung cancer live longer or well enough to continue treatment.

  Recruiting Phase 2 Biokin (Shanghai) Biopharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT07654400

• BL-M14D1 plus atezolizumab vs standard therapy in first-line extensive-stage small cell lung cancer

  A first-line treatment for adults with extensive-stage small cell lung cancer tests whether adding BL-M14D1 to atezolizumab and standard chemotherapy helps more than standard care.

  Recruiting at 7 sites Phase 3 SystImmune Inc. · Springdale, Arkansas and 61 other locations · NCT07625644

• PD-L1 PET/CT to see primary and metastatic PD-L1-related lesions in adults

  This study tests whether 68Ga/18F-PD-L1 PET/CT can help detect primary and metastatic PD-L1-related tumors in adults.

  Recruiting at 3 sites Tianjin Medical University · Hefei, Anhui and 2 other locations · NCT07618936

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.